home
Bringing New Horizons to Therapy
Investor Information
Event: May 18, 2010 EDAP TMS is presently accelerating adoption of HIFU therapy as a new standard of care for localized prostate cancer in Europe where the company is the clear market leader while securing US approval through an active FDA Clinical Study at leading urology centers.
Recent Releases
Jul 29, 2010
EDAP Schedules Webcast and Conference Call for Second Quarter 2010 Results
Jun 29, 2010
EDAP Announces New Ablatherm HIFU Site at Cleveland Clinic Canada in Toronto, Canada
Events & Presentations
Aug 24, 2010 at 8:30 AM ET
EDAP Second Quarter 2010 Results Conference Call
Nov 17, 2009 at 8:30 AM ET
EDAP Third Quarter 2009 Results Conference Call
IR Contact
Stock Information
|
NASDAQ : EDAP Last Price : 2.12 Change : 0.01  0.474%Day High : 2.17 Day Low : 2.10 Year High : 5.95 Year Low : 1.23 Volume : 16,400 |